ReachRxResearch
Home
Research
Sign Up
Study limitation
Back to Research Hub
  1. Home
  2. Research Hub
  3. Study limitation

Compartment-specific PPARδ activity controls the outcome of cancer–immune cell competition and immunotherapy efficacy

Study limitation reported by the research below: “The PPARδ agonist GW501516 (Cardarine) has prior safety concerns including potential pro-tumorigenic effects in cancer cells—compartment-specific delivery would be essential for any clinical translation.”

Papers